Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Feb;133(2):187-9.
doi: 10.1016/j.thromres.2013.11.027. Epub 2013 Dec 1.

Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications

Affiliations
Clinical Trial

Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications

Rose Willemze et al. Thromb Res. 2014 Feb.

Abstract

Antiphospholipid syndrome (APS) is defined by the association of autoantibodies to certain phospholipid-binding proteins with arterial or venous thrombosis ('AT' or 'VT', respectively), and/or pregnancy-related morbidity (PM). Antiphospholipid antibodies (aPLA) promote activation of several cell types including monocytes, resulting in procoagulant tissue factor (TF) expression that may contribute to the vascular complications. Since TF synthesis by monocytes is frequently accompanied by release of TF-bearing microparticles, we hypothesized that plasma microparticle TF activity (MP-TF) may be elevated in APS patients and contribute to thrombosis and/or PM. Platelet-poor plasma specimens were obtained from 30 patients with definite APS and 72 patients with asymptomatic aPLA from the Antiphospholipid Syndrome Collaborative Registry (APSCORE). MP-TF was measured by an in-house factor Xa generation assay. The two groups were well matched for gender, age, ethnicity, proportions with underlying SLE, and aPLA profiles. MP-TF (median and (IQR)) in asymptomatic aPLA subjects was 0.09 pg/mL (0.05-0.14) compared to 0.13 pg/mL (0.10-0.17) in APS (p < 0.001). No differences in MP-TF levels were observed between APS subjects with PM, thrombosis, or PM+thrombosis. Similarly, among subjects with either APS or asymptomatic aPLA, MP-TF did not differ in the presence or absence of underlying SLE. Prospective studies will be required to determine if plasma MP-TF activity is causally related to thrombotic or gestational complications in APS.

Keywords: Antiphospholipid syndrome; Microparticle; Pregnancy; Thrombosis; Tissue factor.

PubMed Disclaimer

Conflict of interest statement

Statement of conflicts of interest: None of the authors has any conflict of interest to report

Figures

Figure 1
Figure 1
Figure 1A: MP-TF activity in subjects with anti-phospholipid syndrome (APS) and control subjects with asymptomatic anti-phospholipid antibodies (APL). Data are presented as medians and inter-quartile ranges. [***p<0.001]. Figure 1B: MP-TF activity according to sub-groups. Data are presented as medians and inter-quartile ranges. Abbreviations: Th = history of thrombosis; PM = history of pregnancy-related morbidity; aPL (−) = asymptomatic with antiphospholipid antibodies but without SLE; aPL (+) = asymptomatic with antiphospholipid antibodies and SLE.

References

    1. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. The New England journal of medicine. 2013;368:1033–1044. - PubMed
    1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, PGDEG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) Journal of thrombosis and haemostasis : JTH. 2006;4:295–306. - PubMed
    1. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498–1509. - PubMed
    1. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thrombosis and haemostasis. 1998;79:276–281. - PubMed
    1. Atsumi T, Khamashta MA, Amengual O, Hughes GR. Up-regulated tissue factor expression in antiphospholipid syndrome. Thrombosis and haemostasis. 1997;77:222–223. - PubMed

Publication types

Substances